• Cécile Guendouz, Véronique Quenardelle, Nolwenn Riou-Comte, Pascal Welfringer, Valérie Wolff, Stéphane Zuily, Lavinia Jager, Lisa Humbertjean Selton, Gioia Mione, Raoul Pop, Benjamin Gory, and Sébastien Richard.
• Department of Neurology, Université de Lorraine, CHRU-Nancy, Stroke Unit, CIC-P 1433, INSERMU1116, Nancy.
• Medicine (Baltimore). 2021 Mar 12; 100 (10): e24708.

RationalePathogeny of thrombosis in COVID-19 is related to interaction of SARS-Cov-2 with vascular wall through the angiotensin converting enzyme 2 (ACE2) receptor. This induces 2 pathways with immunothrombosis from activated endothelium (cytokine storm, leukocyte and platelet recruitment, and activation of coagulation extrinsic pathway), and rise of angiotensin II levels promoting inflammation. While thrombosis is widely described in COVID-19 patients admitted in intensive care unit, cerebrovascular diseases remains rare, in particular cerebral venous thrombosis (CVT).Patient ConcernsWe describe 2 cases of women admitted during the spring of 2020 for intracranial hypertension signs, in stroke units in Great-east, a French area particularly affected by COVID-19 pandemia.DiagnosesCerebral imaging revealed extended CVT in both cases. The first case described was more serious due to right supratentorial venous infarction with hemorrhagic transformation leading to herniation. Both patients presented typical pneumonia due to SARS-Cov-2 infection, confirmed by reverse transcription polymerase chain reaction on a nasopharyngeal swab in only one.InterventionsThe first patient had to undergo decompressive craniectomy, and both patients were treated with anticoagulation therapy.OutcomesFavorable outcome was observed for 1 patient. Persistent coma, due to bi thalamic infarction, remained for the other with more serious presentation.LessonsCVT, as a serious complication of COVID-19, has to be searched in all patients with intracranial hypertension syndrome. Data about anticoagulation therapy to prevent such serious thrombosis in SARS-Cov-2 infection are lacking, in particular in patients with mild and moderate COVID-19.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

31 keywords...

hide…